This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamic…

Mesothelin-Expressing TumorsEpithelial Ovarian CancerMalignant Pleural Mesothelioma, Advanced+8 more

~Estimated

~$10 – $8,750

Context Therapeutics Inc.NCT06756035

Phase 2

A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer t…

Bile Duct CancerCholangiocarcinomaCholangiocarcinoma Non-resectable+2 more

~Estimated

~$10 – $6,250

Beth Israel Deaconess Medical CenterNCT05655949